The role of N-glycosylation in spike antigenicity for the SARS-CoV-2 gamma variant

The emergence of SARS-CoV-2 variants alters the efficacy of existing immunity towards the viral spike protein, whether acquired from infection or vaccination. Mutations that impact N-glycosylation of spike may be particularly important in influencing antigenicity, but their consequences are difficul...

Full description

Saved in:
Bibliographic Details
Published inGlycobiology (Oxford) Vol. 34; no. 2
Main Authors Pegg, Cassandra L, Modhiran, Naphak, Parry, Rhys H, Liang, Benjamin, Amarilla, Alberto A, Khromykh, Alexander A, Burr, Lucy, Young, Paul R, Chappell, Keith, Schulz, Benjamin L, Watterson, Daniel
Format Journal Article
LanguageEnglish
Published England Oxford University Press 26.03.2024
Subjects
Antibodies, Viral
COVID-19
Editor's Choice
Glycosylation
Humans
Original
SARS-CoV-2
Spike Glycoprotein, Coronavirus
glycoproteomics
coronavirus
mass spectrometry
antibodies
glycoprotein
Online AccessGet full text

Cover

Abstract The emergence of SARS-CoV-2 variants alters the efficacy of existing immunity towards the viral spike protein, whether acquired from infection or vaccination. Mutations that impact N-glycosylation of spike may be particularly important in influencing antigenicity, but their consequences are difficult to predict. Here, we compare the glycosylation profiles and antigenicity of recombinant viral spike of ancestral Wu-1 and the Gamma strain, which has two additional N-glycosylation sites due to amino acid substitutions in the N-terminal domain (NTD). We found that a mutation at residue 20 from threonine to asparagine within the NTD caused the loss of NTD-specific antibody COVA2-17 binding. Glycan site-occupancy analyses revealed that the mutation resulted in N-glycosylation switching to the new sequon at N20 from the native N17 site. Site-specific glycosylation profiles demonstrated distinct glycoform differences between Wu-1, Gamma, and selected NTD variant spike proteins, but these did not affect antibody binding. Finally, we evaluated the specificity of spike proteins against convalescent COVID-19 sera and found reduced cross-reactivity against some mutants, but not Gamma spike compared to Wuhan spike. Our results illustrate the impact of viral divergence on spike glycosylation and SARS-CoV-2 antibody binding profiles.
AbstractList The emergence of SARS-CoV-2 variants alters the efficacy of existing immunity towards the viral spike protein, whether acquired from infection or vaccination. Mutations that impact N -glycosylation of spike may be particularly important in influencing antigenicity, but their consequences are difficult to predict. Here, we compare the glycosylation profiles and antigenicity of recombinant viral spike of ancestral Wu-1 and the Gamma strain, which has two additional N -glycosylation sites due to amino acid substitutions in the N-terminal domain (NTD). We found that a mutation at residue 20 from threonine to asparagine within the NTD caused the loss of NTD-specific antibody COVA2-17 binding. Glycan site-occupancy analyses revealed that the mutation resulted in N -glycosylation switching to the new sequon at N20 from the native N17 site. Site-specific glycosylation profiles demonstrated distinct glycoform differences between Wu-1, Gamma, and selected NTD variant spike proteins, but these did not affect antibody binding. Finally, we evaluated the specificity of spike proteins against convalescent COVID-19 sera and found reduced cross-reactivity against some mutants, but not Gamma spike compared to Wuhan spike. Our results illustrate the impact of viral divergence on spike glycosylation and SARS-CoV-2 antibody binding profiles.
The emergence of SARS-CoV-2 variants alters the efficacy of existing immunity towards the viral spike protein, whether acquired from infection or vaccination. Mutations that impact N-glycosylation of spike may be particularly important in influencing antigenicity, but their consequences are difficult to predict. Here, we compare the glycosylation profiles and antigenicity of recombinant viral spike of ancestral Wu-1 and the Gamma strain, which has two additional N-glycosylation sites due to amino acid substitutions in the N-terminal domain (NTD). We found that a mutation at residue 20 from threonine to asparagine within the NTD caused the loss of NTD-specific antibody COVA2-17 binding. Glycan site-occupancy analyses revealed that the mutation resulted in N-glycosylation switching to the new sequon at N20 from the native N17 site. Site-specific glycosylation profiles demonstrated distinct glycoform differences between Wu-1, Gamma, and selected NTD variant spike proteins, but these did not affect antibody binding. Finally, we evaluated the specificity of spike proteins against convalescent COVID-19 sera and found reduced cross-reactivity against some mutants, but not Gamma spike compared to Wuhan spike. Our results illustrate the impact of viral divergence on spike glycosylation and SARS-CoV-2 antibody binding profiles.The emergence of SARS-CoV-2 variants alters the efficacy of existing immunity towards the viral spike protein, whether acquired from infection or vaccination. Mutations that impact N-glycosylation of spike may be particularly important in influencing antigenicity, but their consequences are difficult to predict. Here, we compare the glycosylation profiles and antigenicity of recombinant viral spike of ancestral Wu-1 and the Gamma strain, which has two additional N-glycosylation sites due to amino acid substitutions in the N-terminal domain (NTD). We found that a mutation at residue 20 from threonine to asparagine within the NTD caused the loss of NTD-specific antibody COVA2-17 binding. Glycan site-occupancy analyses revealed that the mutation resulted in N-glycosylation switching to the new sequon at N20 from the native N17 site. Site-specific glycosylation profiles demonstrated distinct glycoform differences between Wu-1, Gamma, and selected NTD variant spike proteins, but these did not affect antibody binding. Finally, we evaluated the specificity of spike proteins against convalescent COVID-19 sera and found reduced cross-reactivity against some mutants, but not Gamma spike compared to Wuhan spike. Our results illustrate the impact of viral divergence on spike glycosylation and SARS-CoV-2 antibody binding profiles.
The emergence of SARS-CoV-2 variants alters the efficacy of existing immunity towards the viral spike protein, whether acquired from infection or vaccination. Mutations that impact N-glycosylation of spike may be particularly important in influencing antigenicity, but their consequences are difficult to predict. Here, we compare the glycosylation profiles and antigenicity of recombinant viral spike of ancestral Wu-1 and the Gamma strain, which has two additional N-glycosylation sites due to amino acid substitutions in the N-terminal domain (NTD). We found that a mutation at residue 20 from threonine to asparagine within the NTD caused the loss of NTD-specific antibody COVA2-17 binding. Glycan site-occupancy analyses revealed that the mutation resulted in N-glycosylation switching to the new sequon at N20 from the native N17 site. Site-specific glycosylation profiles demonstrated distinct glycoform differences between Wu-1, Gamma, and selected NTD variant spike proteins, but these did not affect antibody binding. Finally, we evaluated the specificity of spike proteins against convalescent COVID-19 sera and found reduced cross-reactivity against some mutants, but not Gamma spike compared to Wuhan spike. Our results illustrate the impact of viral divergence on spike glycosylation and SARS-CoV-2 antibody binding profiles.
Author Pegg, Cassandra L
Chappell, Keith
Liang, Benjamin
Parry, Rhys H
Modhiran, Naphak
Burr, Lucy
Amarilla, Alberto A
Khromykh, Alexander A
Young, Paul R
Watterson, Daniel
Schulz, Benjamin L
Author_xml – sequence: 1
  givenname: Cassandra L
  orcidid: 0000-0002-6080-7047
  surname: Pegg
  fullname: Pegg, Cassandra L
  organization: School of Chemistry and Molecular Bioscience, Chemistry Building 68, Cooper Road, University of Queensland, St Lucia, Queensland 4072, Australia
– sequence: 2
  givenname: Naphak
  surname: Modhiran
  fullname: Modhiran, Naphak
  organization: Australian Institute for Bioengineering and Nanotechnology, Building 75, Corner College Road and Cooper Road, University of Queensland, St Lucia, Queensland 4072, Australia
– sequence: 3
  givenname: Rhys H
  surname: Parry
  fullname: Parry, Rhys H
  organization: School of Chemistry and Molecular Bioscience, Chemistry Building 68, Cooper Road, University of Queensland, St Lucia, Queensland 4072, Australia
– sequence: 4
  givenname: Benjamin
  surname: Liang
  fullname: Liang, Benjamin
  organization: School of Chemistry and Molecular Bioscience, Chemistry Building 68, Cooper Road, University of Queensland, St Lucia, Queensland 4072, Australia
– sequence: 5
  givenname: Alberto A
  surname: Amarilla
  fullname: Amarilla, Alberto A
  organization: School of Chemistry and Molecular Bioscience, Chemistry Building 68, Cooper Road, University of Queensland, St Lucia, Queensland 4072, Australia
– sequence: 6
  givenname: Alexander A
  surname: Khromykh
  fullname: Khromykh, Alexander A
  organization: Australian Infectious Disease Research Centre, Global Virus Network Centre of Excellence, Brisbane, Queensland 4072 and 4006, Australia
– sequence: 7
  givenname: Lucy
  surname: Burr
  fullname: Burr, Lucy
  organization: Department of Respiratory Medicine, Mater Health Services, Raymond Terrace, South Brisbane, Queensland 4101, Australia
– sequence: 8
  givenname: Paul R
  surname: Young
  fullname: Young, Paul R
  organization: Australian Infectious Disease Research Centre, Global Virus Network Centre of Excellence, Brisbane, Queensland 4072 and 4006, Australia
– sequence: 9
  givenname: Keith
  surname: Chappell
  fullname: Chappell, Keith
  organization: Australian Infectious Disease Research Centre, Global Virus Network Centre of Excellence, Brisbane, Queensland 4072 and 4006, Australia
– sequence: 10
  givenname: Benjamin L
  surname: Schulz
  fullname: Schulz, Benjamin L
  organization: Australian Infectious Disease Research Centre, Global Virus Network Centre of Excellence, Brisbane, Queensland 4072 and 4006, Australia
– sequence: 11
  givenname: Daniel
  surname: Watterson
  fullname: Watterson, Daniel
  organization: Australian Infectious Disease Research Centre, Global Virus Network Centre of Excellence, Brisbane, Queensland 4072 and 4006, Australia
BackLink https://www.ncbi.nlm.nih.gov/pubmed/38048640$$D View this record in MEDLINE/PubMed
BookMark eNpVkU1PwzAMhiMEgjG4ckQ5cilLmrRNT2ia-JImkMbHNUozdwTaZCTdUP89gQ0EJ1vy68f260O0a50FhE4oOaekZKNF02tXjfSHmpOy2EEDynOSpDxlu3_yA3QYwishNKci20cHTBAuck4GaPb4Ati7BrCr8V3yjQt9ozrjLDYWh6V5A6xsZxZgjTZdj2vncRe7Hsazh2TinpMUL1TbKrxW3kTlEdqrVRPgeBuH6Onq8nFyk0zvr28n42miGc-7pOY5iBqynFBdQZ1lrCzmoipYRgtRFwCVSDkFwVVRlSpWtchonpZFvEpXVcqG6GLDXa6qFuYabOdVI5fetMr30ikj_1eseZELt5bRuLyMrEg42xK8e19B6GRrgoamURbcKshUlIJRzhiN0vONVHsXgof6dw4lX0AmN5-Q20_EhtO_2_3Kf6xnn8XriNs
Cites_doi 10.1016/j.mcpro.2021.100103
10.1126/scitranslmed.abm0899
10.1038/s41586-020-2571-7
10.1016/j.cell.2020.09.018
10.1038/s41586-021-03925-1
10.1016/j.jmb.2021.167332
10.3201/eid2704.210138
10.1016/j.celrep.2021.108890
10.3389/fimmu.2022.963023
10.1101/2021.09.12.459978
10.1093/glycob/cwy093
10.3762/bjoc.16.180
10.1016/S2666-5247(21)00129-4
10.1038/s41592-022-01451-0
10.1126/science.abh2644
10.7554/eLife.61552
10.1021/acs.biochem.1c00279
10.1016/j.cell.2021.03.028
10.1038/s41467-021-24963-3
10.1002/cti2.1269
10.1021/bi500681p
10.1016/S1473-3099(21)00200-0
10.1039/D1SC04832E
10.1038/s41589-021-00924-1
10.1016/j.ab.2020.113625
10.1016/j.chom.2021.04.007
10.1016/j.chom.2020.08.004
10.1101/2020.05.13.092478
10.1126/science.abl9463
10.1016/j.chom.2021.03.005
10.1093/glycob/cwy021
10.1073/pnas.2106535118
10.1038/s41598-021-02904-w
10.1038/s41576-021-00408-x
10.1371/journal.ppat.1009282
10.1021/acscentsci.1c00058
10.1038/s41557-021-00758-3
10.1038/s41591-021-01378-7
10.1016/j.chembiol.2015.06.017
10.1126/science.abc6952
10.1038/s42003-021-01903-x
10.1021/acscentsci.0c01056
10.1126/sciadv.abg7607
10.1126/science.abb9983
10.1016/j.cell.2021.07.007
10.1093/glycob/cwab102
10.1016/j.cell.2021.03.055
10.1007/s00109-021-02092-0
10.1016/j.jmb.2022.167928
10.1016/j.sbi.2022.102402
10.1038/s41586-020-2381-y
10.1126/science.abg5268
10.1016/j.bbagen.2019.05.012
10.1016/j.chom.2021.04.010
10.1126/sciadv.abj5365
10.1016/j.cell.2020.09.033
10.1038/s41586-020-2349-y
10.1126/science.abb7269
10.1038/s41579-021-00573-0
10.1038/srep08926
10.1126/science.abb9425
10.1007/s10719-020-09922-2
10.1126/science.abc5902
10.1093/nar/gkv468
10.1371/journal.ppat.1009576
10.1038/nature11414
10.1038/s41586-021-03398-2
ContentType Journal Article
Copyright The Author(s) 2023. Published by Oxford University Press.
The Author(s) 2023. Published by Oxford University Press. 2023
Copyright_xml – notice: The Author(s) 2023. Published by Oxford University Press.
– notice: The Author(s) 2023. Published by Oxford University Press. 2023
DBID CGR
CUY
CVF
ECM
EIF
NPM
AAYXX
CITATION
7X8
5PM
DOI 10.1093/glycob/cwad097
DatabaseName Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
CrossRef
MEDLINE - Academic
PubMed Central (Full Participant titles)
DatabaseTitle MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
CrossRef
MEDLINE - Academic
DatabaseTitleList
MEDLINE - Academic
CrossRef
MEDLINE
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Anatomy & Physiology
Chemistry
EISSN 1460-2423
ExternalDocumentID 10_1093_glycob_cwad097
38048640
Genre Research Support, Non-U.S. Gov't
Journal Article
GrantInformation_xml – fundername: National Health and Medical Research Council
  grantid: APP1202445
– fundername: ;
  grantid: APP1202445; APP1186699; 2012883
GroupedDBID ---
-E4
.2P
.I3
.ZR
0R~
1TH
29I
2WC
4.4
482
48X
5GY
5VS
5WA
5WD
70D
AABZA
AACZT
AAHBH
AAIMJ
AAJKP
AAMDB
AAMVS
AAOGV
AAPNW
AAPQZ
AAPXW
AARHZ
AAUAY
AAVAP
AAVLN
ABEJV
ABEUO
ABIXL
ABJNI
ABKDP
ABMNT
ABNHQ
ABNKS
ABPTD
ABQLI
ABWST
ABXVV
ABZBJ
ACGFS
ACIWK
ACNCT
ACPRK
ACUFI
ACUTJ
ACUTO
ADBBV
ADEYI
ADEZT
ADFTL
ADGKP
ADGZP
ADHKW
ADHZD
ADIPN
ADJQC
ADOCK
ADQBN
ADRIX
ADRTK
ADVEK
ADYVW
ADZTZ
ADZXQ
AEGPL
AEJOX
AEKSI
AELWJ
AEMDU
AENEX
AENZO
AEPUE
AETBJ
AEWNT
AFFZL
AFGWE
AFIYH
AFOFC
AFRAH
AFXEN
AGINJ
AGKEF
AGQXC
AGSYK
AHMBA
AHXPO
AIJHB
AJEEA
AKHUL
AKWXX
ALMA_UNASSIGNED_HOLDINGS
ALUQC
APIBT
APWMN
ARIXL
ATGXG
AXUDD
AYOIW
BAWUL
BAYMD
BCRHZ
BEYMZ
BHONS
BQDIO
BSWAC
BTRTY
BVRKM
C45
CDBKE
CGR
CS3
CUY
CVF
CZ4
DAKXR
DILTD
DU5
D~K
E3Z
EBS
ECM
EE~
EIF
F5P
F9B
FHSFR
FLUFQ
FOEOM
FOTVD
FQBLK
GAUVT
GJXCC
H5~
HAR
HW0
HZ~
IOX
J21
KAQDR
KOP
KQ8
KSI
KSN
M-Z
M49
N9A
NGC
NLBLG
NOMLY
NOYVH
NPM
NU-
O9-
OAWHX
OBOKY
OBS
OCZFY
ODMLO
OEB
OJQWA
OJZSN
OK1
OPAEJ
OVD
OWPYF
P2P
PAFKI
PEELM
PQQKQ
Q1.
Q5Y
R44
RD5
RHF
ROL
ROX
RUSNO
RW1
RXO
TEORI
TJX
TLC
TR2
WOQ
X7H
Y6R
YAYTL
YKOAZ
YXANX
ZKX
~91
~KM
AAYXX
AHMMS
CITATION
7X8
5PM
AASNB
ID FETCH-LOGICAL-c346t-f46e8fe5601cbef55397d8b735178f7eeb8241e84a7b9a539c8516297146cbb23
ISSN 1460-2423
0959-6658
IngestDate Tue Sep 17 21:29:27 EDT 2024
Thu Dec 05 23:05:46 EST 2024
Fri Dec 06 05:20:30 EST 2024
Sat Nov 02 12:29:46 EDT 2024
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 2
Keywords glycoproteomics
coronavirus
mass spectrometry
antibodies
glycoprotein
Language English
License The Author(s) 2023. Published by Oxford University Press.
https://creativecommons.org/licenses/by/4.0
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.
LinkModel OpenURL
MergedId FETCHMERGED-LOGICAL-c346t-f46e8fe5601cbef55397d8b735178f7eeb8241e84a7b9a539c8516297146cbb23
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
Cassandra L. Pegg and Naphak Modhiran contributed equally.
ORCID 0000-0002-6080-7047
OpenAccessLink https://pubmed.ncbi.nlm.nih.gov/PMC10969516
PMID 38048640
PQID 2898314331
PQPubID 23479
ParticipantIDs pubmedcentral_primary_oai_pubmedcentral_nih_gov_10969516
proquest_miscellaneous_2898314331
crossref_primary_10_1093_glycob_cwad097
pubmed_primary_38048640
PublicationCentury 2000
PublicationDate 2024-03-26
PublicationDateYYYYMMDD 2024-03-26
PublicationDate_xml – month: 03
  year: 2024
  text: 2024-03-26
  day: 26
PublicationDecade 2020
PublicationPlace England
PublicationPlace_xml – name: England
PublicationTitle Glycobiology (Oxford)
PublicationTitleAlternate Glycobiology
PublicationYear 2024
Publisher Oxford University Press
Publisher_xml – name: Oxford University Press
References Shi (2024032804010408000_ref47) 2020; 584
Tao (2024032804010408000_ref53) 2021; 22
Yuan (2024032804010408000_ref66) 2020; 368
Kuo (2024032804010408000_ref25) 2022; 32
Casalino (2024032804010408000_ref7) 2020; 6
Cerutti (2024032804010408000_ref8) 2021; 29
Malaby (2024032804010408000_ref30) 2014; 53
Harbison (2024032804010408000_ref20) 2022; 13
Lok (2024032804010408000_ref29) 2021; 29
Naveca (2024032804010408000_ref35) 2021; 27
Nguyen (2024032804010408000_ref37) 2022; 18
Wang (2024032804010408000_ref56) 2021; 11
Imai (2024032804010408000_ref23) 2021; 118
Reis (2024032804010408000_ref44) 2021; 99
Watanabe (2024032804010408000_ref59) 2019; 1863
Zhang (2024032804010408000_ref68) 2021; 374
McCallum (2024032804010408000_ref31) 2021; 184
Murray (2024032804010408000_ref34) 2015; 22
Huang (2024032804010408000_ref22) 2022; 14
Kang (2024032804010408000_ref24) 2021; 184
Lempp (2024032804010408000_ref27) 2021; 598
Praissman (2024032804010408000_ref42) 2021; 20
Rees-Spear (2024032804010408000_ref43) 2021; 34
Pelingon (2024032804010408000_ref39) 2020; 596
Yang (2024032804010408000_ref63) 2021
Modhiran (2024032804010408000_ref33) 2021; 371
Phung (2024032804010408000_ref40) 2020; 16
Brouwer (2024032804010408000_ref4) 2020; 369
Sztain (2024032804010408000_ref52) 2021; 13
Young (2024032804010408000_ref65) 2022; 13
Watterson (2024032804010408000_ref61) 2021; 10
Chawla (2024032804010408000_ref10) 2022; 75
Harvey (2024032804010408000_ref21) 2021; 19
Newby (2024032804010408000_ref36) 2022; 435
Souza (2024032804010408000_ref50) 2021; 2
Bagdonaite (2024032804010408000_ref2) 2018; 28
Wang (2024032804010408000_ref57) 2021; 29
Fujino (2024032804010408000_ref19) 2021; 27
Faria (2024032804010408000_ref18) 2021; 372
Ekiert (2024032804010408000_ref17) 2012; 489
Metsalu (2024032804010408000_ref32) 2015; 43
Dejnirattisai (2024032804010408000_ref15) 2021; 184
Chappell (2024032804010408000_ref9) 2021; 21
Chawla (2024032804010408000_ref11) 2022; 434
Pinto (2024032804010408000_ref41) 2020; 583
Allen (2024032804010408000_ref1) 2021; 60
Voss (2024032804010408000_ref55) 2021; 372
Chiodo (2024032804010408000_ref13) 2020
Rosa (2024032804010408000_ref45) 2021; 7
Chi (2024032804010408000_ref12) 2020; 369
Shajahan (2024032804010408000_ref46) 2022; 13
Bouwman (2024032804010408000_ref3) 2021; 17
Watanabe (2024032804010408000_ref60) 2020; 369
Dugan (2024032804010408000_ref16) 2022; 19
Sun (2024032804010408000_ref51) 2021; 12
Zacchi (2024032804010408000_ref67) 2021; 4
Yang (2024032804010408000_ref62) 2020; 9
Lee (2024032804010408000_ref26) 2015; 5
Shrimal (2024032804010408000_ref48) 2013; 126
Shrimal (2024032804010408000_ref49) 2019; 29
Caniels (2024032804010408000_ref6) 2021
Thépaut (2024032804010408000_ref54) 2021; 17
Brun (2024032804010408000_ref5) 2021; 7
Liu (2024032804010408000_ref28) 2020; 584
Yao (2024032804010408000_ref64) 2020; 183
Clausen (2024032804010408000_ref14) 2020; 183
Pegg (2024032804010408000_ref38) 2020; 37
Zhao (2024032804010408000_ref69) 2020; 28
Wang (2024032804010408000_ref58) 2021; 593
References_xml – volume: 20
  start-page: 100103
  year: 2021
  ident: 2024032804010408000_ref42
  article-title: Proteomics-based insights into the SARS-CoV-2-mediated COVID-19 pandemic: a review of the first year of research
  publication-title: Mol Cell Proteomics
  doi: 10.1016/j.mcpro.2021.100103
  contributor:
    fullname: Praissman
– volume: 14
  start-page: eabm0899
  issue: 639
  year: 2022
  ident: 2024032804010408000_ref22
  article-title: Vaccination with SARS-CoV-2 spike protein lacking glycan shields elicits enhanced protective responses in animal models
  publication-title: Sci Transl Med
  doi: 10.1126/scitranslmed.abm0899
  contributor:
    fullname: Huang
– volume: 584
  start-page: 450
  issue: 7821
  year: 2020
  ident: 2024032804010408000_ref28
  article-title: Potent neutralizing antibodies against multiple epitopes on SARS-CoV-2 spike
  publication-title: Nature
  doi: 10.1038/s41586-020-2571-7
  contributor:
    fullname: Liu
– volume: 183
  start-page: 730
  issue: 3
  year: 2020
  ident: 2024032804010408000_ref64
  article-title: Molecular architecture of the SARS-CoV-2 virus
  publication-title: Cell
  doi: 10.1016/j.cell.2020.09.018
  contributor:
    fullname: Yao
– volume: 598
  start-page: 342
  issue: 7880
  year: 2021
  ident: 2024032804010408000_ref27
  article-title: Lectins enhance SARS-CoV-2 infection and influence neutralizing antibodies
  publication-title: Nature
  doi: 10.1038/s41586-021-03925-1
  contributor:
    fullname: Lempp
– volume: 434
  start-page: 167332
  issue: 2
  year: 2022
  ident: 2024032804010408000_ref11
  article-title: Glycosylation and serological reactivity of an expression-enhanced SARS-CoV-2 viral spike mimetic
  publication-title: J Mol Biol
  doi: 10.1016/j.jmb.2021.167332
  contributor:
    fullname: Chawla
– volume: 27
  start-page: 1243
  issue: 4
  year: 2021
  ident: 2024032804010408000_ref19
  article-title: Novel SARS-CoV-2 variant in travelers from Brazil to Japan
  publication-title: Emerg Infect Dis
  doi: 10.3201/eid2704.210138
  contributor:
    fullname: Fujino
– volume: 34
  start-page: 108890
  issue: 12
  year: 2021
  ident: 2024032804010408000_ref43
  article-title: The effect of spike mutations on SARS-CoV-2 neutralization
  publication-title: Cell Rep
  doi: 10.1016/j.celrep.2021.108890
  contributor:
    fullname: Rees-Spear
– volume: 13
  start-page: 963023
  year: 2022
  ident: 2024032804010408000_ref65
  article-title: A platform technology for generating subunit vaccines against diverse viral pathogens
  publication-title: Front Immunol
  doi: 10.3389/fimmu.2022.963023
  contributor:
    fullname: Young
– volume-title: bioRxiv.
  year: 2021
  ident: 2024032804010408000_ref63
  article-title: Structure-activity relationships of B.1.617 and other SARS-CoV-2 spike variants
  doi: 10.1101/2021.09.12.459978
  contributor:
    fullname: Yang
– volume: 29
  start-page: 288
  issue: 4
  year: 2019
  ident: 2024032804010408000_ref49
  article-title: Oligosaccharyltransferase structures provide novel insight into the mechanism of asparagine-linked glycosylation in prokaryotic and eukaryotic cells
  publication-title: Glycobiology
  doi: 10.1093/glycob/cwy093
  contributor:
    fullname: Shrimal
– volume: 16
  start-page: 2127
  year: 2020
  ident: 2024032804010408000_ref40
  article-title: GlypNirO: an automated workflow for quantitative N- and O-linked glycoproteomic data analysis
  publication-title: Beilstein J Org Chem
  doi: 10.3762/bjoc.16.180
  contributor:
    fullname: Phung
– volume: 2
  start-page: e527
  issue: 10
  year: 2021
  ident: 2024032804010408000_ref50
  article-title: Neutralisation of SARS-CoV-2 lineage P.1 by antibodies elicited through natural SARS-CoV-2 infection or vaccination with an inactivated SARS-CoV-2 vaccine: an immunological study
  publication-title: Lancet Microbe
  doi: 10.1016/S2666-5247(21)00129-4
  contributor:
    fullname: Souza
– volume: 19
  start-page: 384
  issue: 4
  year: 2022
  ident: 2024032804010408000_ref16
  article-title: Advances in glycoscience to understand viral infection and colonization
  publication-title: Nat Methods
  doi: 10.1038/s41592-022-01451-0
  contributor:
    fullname: Dugan
– volume: 372
  start-page: 815
  issue: 6544
  year: 2021
  ident: 2024032804010408000_ref18
  article-title: Genomics and epidemiology of the P.1 SARS-CoV-2 lineage in Manaus, Brazil
  publication-title: Science
  doi: 10.1126/science.abh2644
  contributor:
    fullname: Faria
– volume: 9
  start-page: e61552
  year: 2020
  ident: 2024032804010408000_ref62
  article-title: Inhibition of SARS-CoV-2 viral entry upon blocking N- and O-glycan elaboration
  publication-title: elife
  doi: 10.7554/eLife.61552
  contributor:
    fullname: Yang
– volume: 60
  start-page: 2153
  issue: 27
  year: 2021
  ident: 2024032804010408000_ref1
  article-title: Site-specific steric control of SARS-CoV-2 spike glycosylation
  publication-title: Biochemistry
  doi: 10.1021/acs.biochem.1c00279
  contributor:
    fullname: Allen
– volume: 184
  start-page: 2332
  issue: 9
  year: 2021
  ident: 2024032804010408000_ref31
  article-title: N-terminal domain antigenic mapping reveals a site of vulnerability for SARS-CoV-2
  publication-title: Cell
  doi: 10.1016/j.cell.2021.03.028
  contributor:
    fullname: McCallum
– volume: 12
  start-page: 4676
  issue: 1
  year: 2021
  ident: 2024032804010408000_ref51
  article-title: Potent neutralizing nanobodies resist convergent circulating variants of SARS-CoV-2 by targeting diverse and conserved epitopes
  publication-title: Nat Commun
  doi: 10.1038/s41467-021-24963-3
  contributor:
    fullname: Sun
– volume: 10
  start-page: e1269
  issue: 4
  year: 2021
  ident: 2024032804010408000_ref61
  article-title: Preclinical development of a molecular clamp-stabilised subunit vaccine for severe acute respiratory syndrome coronavirus 2
  publication-title: Clin Transl Immunology
  doi: 10.1002/cti2.1269
  contributor:
    fullname: Watterson
– volume: 53
  start-page: 4884
  issue: 30
  year: 2014
  ident: 2024032804010408000_ref30
  article-title: The middle X residue influences cotranslational N-glycosylation consensus site skipping
  publication-title: Biochemistry
  doi: 10.1021/bi500681p
  contributor:
    fullname: Malaby
– volume: 21
  start-page: 1383
  issue: 10
  year: 2021
  ident: 2024032804010408000_ref9
  article-title: Safety and immunogenicity of an MF59-adjuvanted spike glycoprotein-clamp vaccine for SARS-CoV-2: a randomised, double-blind, placebo-controlled, phase 1 trial
  publication-title: Lancet Infect Dis
  doi: 10.1016/S1473-3099(21)00200-0
  contributor:
    fullname: Chappell
– volume: 13
  start-page: 386
  issue: 2
  year: 2022
  ident: 2024032804010408000_ref20
  article-title: Fine-tuning the spike: role of the nature and topology of the glycan shield in the structure and dynamics of the SARS-CoV-2 S
  publication-title: Chem Sci
  doi: 10.1039/D1SC04832E
  contributor:
    fullname: Harbison
– volume: 18
  start-page: 81
  issue: 1
  year: 2022
  ident: 2024032804010408000_ref37
  article-title: Sialic acid-containing glycolipids mediate binding and viral entry of SARS-CoV-2
  publication-title: Nat Chem Biol
  doi: 10.1038/s41589-021-00924-1
  contributor:
    fullname: Nguyen
– volume: 596
  start-page: 113625
  year: 2020
  ident: 2024032804010408000_ref39
  article-title: Glycoproteomic measurement of site-specific polysialylation
  publication-title: Anal Biochem
  doi: 10.1016/j.ab.2020.113625
  contributor:
    fullname: Pelingon
– volume: 29
  start-page: 747
  issue: 5
  year: 2021
  ident: 2024032804010408000_ref57
  article-title: Increased resistance of SARS-CoV-2 variant P.1 to antibody neutralization
  publication-title: Cell Host Microbe
  doi: 10.1016/j.chom.2021.04.007
  contributor:
    fullname: Wang
– volume: 28
  start-page: 586
  issue: 4
  year: 2020
  ident: 2024032804010408000_ref69
  article-title: Virus-receptor interactions of glycosylated SARS-CoV-2 spike and human ACE2 receptor
  publication-title: Cell Host Microbe
  doi: 10.1016/j.chom.2020.08.004
  contributor:
    fullname: Zhao
– volume-title: bioRxiv
  year: 2020
  ident: 2024032804010408000_ref13
  article-title: Novel ACE2-independent carbohydrate-binding of SARS-CoV-2 spike protein to host lectins and lung microbiota
  doi: 10.1101/2020.05.13.092478
  contributor:
    fullname: Chiodo
– volume: 374
  start-page: 1353
  issue: 6573
  year: 2021
  ident: 2024032804010408000_ref68
  article-title: Membrane fusion and immune evasion by the spike protein of SARS-CoV-2 Delta variant
  publication-title: Science
  doi: 10.1126/science.abl9463
  contributor:
    fullname: Zhang
– volume: 29
  start-page: 819
  issue: 5
  year: 2021
  ident: 2024032804010408000_ref8
  article-title: Potent SARS-CoV-2 neutralizing antibodies directed against spike N-terminal domain target a single supersite
  publication-title: Cell Host Microbe
  doi: 10.1016/j.chom.2021.03.005
  contributor:
    fullname: Cerutti
– volume: 28
  start-page: 443
  issue: 7
  year: 2018
  ident: 2024032804010408000_ref2
  article-title: Global aspects of viral glycosylation
  publication-title: Glycobiology
  doi: 10.1093/glycob/cwy021
  contributor:
    fullname: Bagdonaite
– volume: 118
  start-page: e2106535118
  issue: 27
  year: 2021
  ident: 2024032804010408000_ref23
  article-title: Characterization of a new SARS-CoV-2 variant that emerged in Brazil
  publication-title: Proc Natl Acad Sci U S A
  doi: 10.1073/pnas.2106535118
  contributor:
    fullname: Imai
– volume: 11
  start-page: 23561
  issue: 1
  year: 2021
  ident: 2024032804010408000_ref56
  article-title: N-glycosylation profiles of the SARS-CoV-2 spike D614G mutant and its ancestral protein characterized by advanced mass spectrometry
  publication-title: Sci Rep
  doi: 10.1038/s41598-021-02904-w
  contributor:
    fullname: Wang
– volume: 22
  start-page: 757
  issue: 12
  year: 2021
  ident: 2024032804010408000_ref53
  article-title: The biological and clinical significance of emerging SARS-CoV-2 variants
  publication-title: Nat Rev Genet
  doi: 10.1038/s41576-021-00408-x
  contributor:
    fullname: Tao
– volume: 17
  start-page: e1009282
  issue: 2
  year: 2021
  ident: 2024032804010408000_ref3
  article-title: Multimerization- and glycosylation-dependent receptor binding of SARS-CoV-2 spike proteins
  publication-title: PLoS Pathog
  doi: 10.1371/journal.ppat.1009282
  contributor:
    fullname: Bouwman
– volume: 7
  start-page: 586
  issue: 4
  year: 2021
  ident: 2024032804010408000_ref5
  article-title: Assessing antigen structural integrity through glycosylation analysis of the SARS-CoV-2 viral spike
  publication-title: ACS Cent Sci
  doi: 10.1021/acscentsci.1c00058
  contributor:
    fullname: Brun
– volume: 13
  start-page: 963
  issue: 10
  year: 2021
  ident: 2024032804010408000_ref52
  article-title: A glycan gate controls opening of the SARS-CoV-2 spike protein
  publication-title: Nat Chem
  doi: 10.1038/s41557-021-00758-3
  contributor:
    fullname: Sztain
– volume: 27
  start-page: 1230
  issue: 7
  year: 2021
  ident: 2024032804010408000_ref35
  article-title: COVID-19 in Amazonas, Brazil, was driven by the persistence of endemic lineages and P.1 emergence
  publication-title: Nat Med
  doi: 10.1038/s41591-021-01378-7
  contributor:
    fullname: Naveca
– volume: 22
  start-page: 1052
  issue: 8
  year: 2015
  ident: 2024032804010408000_ref34
  article-title: Enhanced aromatic sequons increase oligosaccharyltransferase glycosylation efficiency and glycan homogeneity
  publication-title: Chem Biol
  doi: 10.1016/j.chembiol.2015.06.017
  contributor:
    fullname: Murray
– volume: 369
  start-page: 650
  issue: 6504
  year: 2020
  ident: 2024032804010408000_ref12
  article-title: A neutralizing human antibody binds to the N-terminal domain of the spike protein of SARS-CoV-2
  publication-title: Science
  doi: 10.1126/science.abc6952
  contributor:
    fullname: Chi
– volume: 4
  start-page: 390
  issue: 1
  year: 2021
  ident: 2024032804010408000_ref67
  article-title: Coagulation factor IX analysis in bioreactor cell culture supernatant predicts quality of the purified product
  publication-title: Commun Biol
  doi: 10.1038/s42003-021-01903-x
  contributor:
    fullname: Zacchi
– volume: 6
  start-page: 1722
  issue: 10
  year: 2020
  ident: 2024032804010408000_ref7
  article-title: Beyond shielding: the roles of glycans in the SARS-CoV-2 spike protein
  publication-title: ACS Cent Sci
  doi: 10.1021/acscentsci.0c01056
  contributor:
    fullname: Casalino
– volume: 13
  year: 2022
  ident: 2024032804010408000_ref46
  article-title: Site specific N- and O-glycosylation mapping of the spike proteins of SARS-CoV-2 variants of concern
  publication-title: Scientific Reports
  contributor:
    fullname: Shajahan
– volume: 7
  start-page: eabg7607
  issue: 22
  year: 2021
  ident: 2024032804010408000_ref45
  article-title: SARS-CoV-2 can recruit a heme metabolite to evade antibody immunity
  publication-title: Sci Adv
  doi: 10.1126/sciadv.abg7607
  contributor:
    fullname: Rosa
– volume: 369
  start-page: 330
  issue: 6501
  year: 2020
  ident: 2024032804010408000_ref60
  article-title: Site-specific glycan analysis of the SARS-CoV-2 spike
  publication-title: Science
  doi: 10.1126/science.abb9983
  contributor:
    fullname: Watanabe
– volume: 184
  start-page: 4392
  issue: 17
  year: 2021
  ident: 2024032804010408000_ref24
  article-title: A selective sweep in the spike gene has driven SARS-CoV-2 human adaptation
  publication-title: Cell
  doi: 10.1016/j.cell.2021.07.007
  contributor:
    fullname: Kang
– volume: 32
  start-page: 60
  issue: 1
  year: 2022
  ident: 2024032804010408000_ref25
  article-title: Distinct shifts in site-specific glycosylation pattern of SARS-CoV-2 spike proteins associated with arising mutations in the D614G and alpha variants
  publication-title: Glycobiology
  doi: 10.1093/glycob/cwab102
  contributor:
    fullname: Kuo
– volume: 184
  start-page: 2939
  issue: 11
  year: 2021
  ident: 2024032804010408000_ref15
  article-title: Antibody evasion by the P.1 strain of SARS-CoV-2
  publication-title: Cell
  doi: 10.1016/j.cell.2021.03.055
  contributor:
    fullname: Dejnirattisai
– volume: 99
  start-page: 1023
  issue: 8
  year: 2021
  ident: 2024032804010408000_ref44
  article-title: Glycosylation is a key in SARS-CoV-2 infection
  publication-title: J Mol Med (Berl)
  doi: 10.1007/s00109-021-02092-0
  contributor:
    fullname: Reis
– volume: 435
  start-page: 167928
  issue: 4
  year: 2022
  ident: 2024032804010408000_ref36
  article-title: Variations within the glycan shield of SARS-CoV-2 impact viral spike dynamics
  publication-title: J Mol Biol
  doi: 10.1016/j.jmb.2022.167928
  contributor:
    fullname: Newby
– volume: 75
  start-page: 102402
  year: 2022
  ident: 2024032804010408000_ref10
  article-title: Principles of SARS-CoV-2 glycosylation
  publication-title: Curr Opin Struct Biol
  doi: 10.1016/j.sbi.2022.102402
  contributor:
    fullname: Chawla
– volume: 584
  start-page: 120
  issue: 7819
  year: 2020
  ident: 2024032804010408000_ref47
  article-title: A human neutralizing antibody targets the receptor-binding site of SARS-CoV-2
  publication-title: Nature
  doi: 10.1038/s41586-020-2381-y
  contributor:
    fullname: Shi
– volume: 372
  start-page: 1108
  issue: 6546
  year: 2021
  ident: 2024032804010408000_ref55
  article-title: Prevalent, protective, and convergent IgG recognition of SARS-CoV-2 non-RBD spike epitopes
  publication-title: Science
  doi: 10.1126/science.abg5268
  contributor:
    fullname: Voss
– volume: 1863
  start-page: 1480
  issue: 10
  year: 2019
  ident: 2024032804010408000_ref59
  article-title: Exploitation of glycosylation in enveloped virus pathobiology
  publication-title: Biochim Biophys Acta Gen Subj
  doi: 10.1016/j.bbagen.2019.05.012
  contributor:
    fullname: Watanabe
– volume: 29
  start-page: 744
  issue: 5
  year: 2021
  ident: 2024032804010408000_ref29
  article-title: An NTD supersite of attack
  publication-title: Cell Host Microbe
  doi: 10.1016/j.chom.2021.04.010
  contributor:
    fullname: Lok
– volume-title: medRxiv
  year: 2021
  ident: 2024032804010408000_ref6
  article-title: Emerging SARS-CoV-2 variants of concern evade humoral immune responses from infection and vaccination
  doi: 10.1126/sciadv.abj5365
  contributor:
    fullname: Caniels
– volume: 183
  start-page: 1043
  issue: 4
  year: 2020
  ident: 2024032804010408000_ref14
  article-title: SARS-CoV-2 infection depends on cellular heparan sulfate and ACE2
  publication-title: Cell
  doi: 10.1016/j.cell.2020.09.033
  contributor:
    fullname: Clausen
– volume: 583
  start-page: 290
  issue: 7815
  year: 2020
  ident: 2024032804010408000_ref41
  article-title: Cross-neutralization of SARS-CoV-2 by a human monoclonal SARS-CoV antibody
  publication-title: Nature
  doi: 10.1038/s41586-020-2349-y
  contributor:
    fullname: Pinto
– volume: 368
  start-page: 630
  issue: 6491
  year: 2020
  ident: 2024032804010408000_ref66
  article-title: A highly conserved cryptic epitope in the receptor binding domains of SARS-CoV-2 and SARS-CoV
  publication-title: Science
  doi: 10.1126/science.abb7269
  contributor:
    fullname: Yuan
– volume: 19
  start-page: 409
  issue: 7
  year: 2021
  ident: 2024032804010408000_ref21
  article-title: SARS-CoV-2 variants, spike mutations and immune escape
  publication-title: Nat Rev Microbiol
  doi: 10.1038/s41579-021-00573-0
  contributor:
    fullname: Harvey
– volume: 5
  start-page: 8926
  issue: 1
  year: 2015
  ident: 2024032804010408000_ref26
  article-title: Effects of N-glycosylation on protein conformation and dynamics: protein data bank analysis and molecular dynamics simulation study
  publication-title: Sci Rep
  doi: 10.1038/srep08926
  contributor:
    fullname: Lee
– volume: 126
  start-page: 5513
  issue: Pt 23
  year: 2013
  ident: 2024032804010408000_ref48
  article-title: Glycosylation of closely spaced acceptor sites in human glycoproteins
  publication-title: J Cell Sci
  contributor:
    fullname: Shrimal
– volume: 371
  start-page: 190
  issue: 6525
  year: 2021
  ident: 2024032804010408000_ref33
  article-title: A broadly protective antibody that targets the flavivirus NS1 protein
  publication-title: Science
  doi: 10.1126/science.abb9425
  contributor:
    fullname: Modhiran
– volume: 37
  start-page: 471
  issue: 4
  year: 2020
  ident: 2024032804010408000_ref38
  article-title: Identification of novel glycosylation events on human serum-derived factor IX
  publication-title: Glycoconj J
  doi: 10.1007/s10719-020-09922-2
  contributor:
    fullname: Pegg
– volume: 369
  start-page: 643
  issue: 6504
  year: 2020
  ident: 2024032804010408000_ref4
  article-title: Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability
  publication-title: Science
  doi: 10.1126/science.abc5902
  contributor:
    fullname: Brouwer
– volume: 43
  start-page: W566
  issue: W1
  year: 2015
  ident: 2024032804010408000_ref32
  article-title: ClustVis: a web tool for visualizing clustering of multivariate data using principal component analysis and heatmap
  publication-title: Nucleic Acids Res
  doi: 10.1093/nar/gkv468
  contributor:
    fullname: Metsalu
– volume: 17
  start-page: e1009576
  issue: 5
  year: 2021
  ident: 2024032804010408000_ref54
  article-title: DC/L-SIGN recognition of spike glycoprotein promotes SARS-CoV-2 trans-infection and can be inhibited by a glycomimetic antagonist
  publication-title: PLoS Pathog
  doi: 10.1371/journal.ppat.1009576
  contributor:
    fullname: Thépaut
– volume: 489
  start-page: 526
  issue: 7417
  year: 2012
  ident: 2024032804010408000_ref17
  article-title: Cross-neutralization of influenza a viruses mediated by a single antibody loop
  publication-title: Nature
  doi: 10.1038/nature11414
  contributor:
    fullname: Ekiert
– volume: 593
  start-page: 130
  issue: 7857
  year: 2021
  ident: 2024032804010408000_ref58
  article-title: Antibody resistance of SARS-CoV-2 variants B.1.351 and B.1.1.7
  publication-title: Nature
  doi: 10.1038/s41586-021-03398-2
  contributor:
    fullname: Wang
SSID ssj0016185
Score 2.4660661
Snippet The emergence of SARS-CoV-2 variants alters the efficacy of existing immunity towards the viral spike protein, whether acquired from infection or vaccination....
SourceID pubmedcentral
proquest
crossref
pubmed
SourceType Open Access Repository
Aggregation Database
Index Database
SubjectTerms Antibodies, Viral
COVID-19
Editor's Choice
Glycosylation
Humans
Original
SARS-CoV-2
Spike Glycoprotein, Coronavirus
Title The role of N-glycosylation in spike antigenicity for the SARS-CoV-2 gamma variant
URI https://www.ncbi.nlm.nih.gov/pubmed/38048640
https://www.proquest.com/docview/2898314331
https://pubmed.ncbi.nlm.nih.gov/PMC10969516
Volume 34
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1bb9MwFLbKkGAvCDYuHRcZCcFDlS3N1XksFTABrUa3ob1FtuO0gSWpmhQoP4DfzXGca4cQ7CWKcrGj832xjo_P-YzQCy4CKfrhacwlpmaFQmiEukyzuRFycJBFaMji5MnUOT633l_YF73er1bW0jpnh_znH-tKroMqXANcZZXsfyBbNwoX4BzwhSMgDMd_xrhKD5xq88sNT7ONSm6TcYxsGX2VqwO5VNyMeFQmZ0pX83Q0O9XG6WfNGMxpHNPBN5gz06QTqH8n26tEmqQq6Q-VCO81w-l8rpJGsowmwYoO6kjyJA0W0UoFV6d0uaB1QdAJXamV-xkwpCmN-BiVgevXIvlC41IPvAxHGJbMx1I1738rc9yKOzqO0ms_FGrUtRxdrk2b7WG5jHFGzez4ymivlLAK6zI44d9poKts3xb4y7hA3yRSXFBJQ3Vlt08mY2jJAVfTuYFuSkFFuQfDh0_NapQzLLZ2rT-9Fv80j1TnR2XXu-hW1U_Xz7kyednOwW05NWd30Z1yNoJHilr3UE8ke2h_lNA8jTf4JS7ygwsC7KHb42pvwH00A-ZhyTychniLeThKcME83GYeBsAwMA83zMMF83DJvPvo_O2bs_GxVu7OoXHTcnIttBxBQiFn9JyJ0LbBsw0Ic0176JLQFYIR8A4FseDX9yjc5eDcO4bnAtqcMcN8gHaSNBGPENa5tJ4udC8ILAZWDl0aEs8KXGpxMGYfvaps6S-VCIuvkidMXwHglwD00fPK1D6YRC5-0USk68w3iEfMoawP7KOHyvR1WxVmfUQ6oNQPSA327p0kWhRa7BVzDq7_6mO02_xIT9BOvlqLp-Dp5uxZQcPfin2uHw
link.rule.ids 230,314,780,784,885,27924,27925
linkProvider Colorado Alliance of Research Libraries
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=The+role+of+N-glycosylation+in+spike+antigenicity+for+the+SARS-CoV-2+gamma+variant&rft.jtitle=Glycobiology+%28Oxford%29&rft.au=Pegg%2C+Cassandra+L&rft.au=Modhiran%2C+Naphak&rft.au=Parry%2C+Rhys+H&rft.au=Liang%2C+Benjamin&rft.date=2024-03-26&rft.pub=Oxford+University+Press&rft.issn=0959-6658&rft.eissn=1460-2423&rft.volume=34&rft.issue=2&rft_id=info:doi/10.1093%2Fglycob%2Fcwad097&rft_id=info%3Apmid%2F38048640&rft.externalDBID=PMC10969516
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1460-2423&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1460-2423&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1460-2423&client=summon